Monitor for the final pricing supplement to determine share count, price, and net proceeds. The dilutive raise for a going-concern clinical-stage company with negative book value is a clear negative signal. Watch for potential downward pressure on NRXP common stock and NRXPW warrants as the market prices in dilution.
Price Chart
How similar events traded
Executive Summary
NRx Pharmaceuticals filed a preliminary prospectus supplement for an underwritten firm-commitment common stock offering under its existing $150M shelf registration. All key terms (share count, price, net proceeds) are placeholder TBD values, but the offering represents a dilutive capital raise for a clinical-stage biopharma with negative tangible book value (-$0.46/share as of March 31, 2026) and a going-concern audit opinion. The stock closed at $4.62 on June 1, 2026.
Key Facts
- Preliminary prospectus supplement for an underwritten common stock offering; all dollar/share amounts are placeholder TBD values.
- Underwriters: BTIG (lead bookrunner) and Lucid Capital Markets (joint bookrunner); firm-commitment basis with 30-day over-allotment option.
- As of March 31, 2026, net tangible book value was approximately -$16,488,000, or -$0.46 per share.
- 36,228,992 shares outstanding as of May 15, 2026; excludes 687,490 options (weighted avg exercise $8.62), 9,359,710 warrants (weighted avg $7.77), and 32,895 restricted stock awards.
- Audited financial statements include going-concern explanatory paragraphs from both Weinberg & Company and Salberg & Company.
- Proceeds intended for working capital and general corporate purposes; management retains broad discretion.
- 60-day lock-up agreements with officers, directors, and the company.
- Cross-filing context: S-3/A filed Dec 12, 2025 registered up to $150M in securities; this 424B5 is a takedown from that shelf.
Financial Impact
Offering size and price are undisclosed (TBD placeholders). Based on the $150M shelf and the company's negative tangible book value of -$16.5M, the offering could be material relative to current market cap. Dilution to existing shareholders is expected.
Risk Factors
- Dilution to existing shareholders from new share issuance.
- Going-concern risk highlighted in audited financial statements.
- Clinical-stage company with no approved products and negative tangible book value.
- Potential for further dilutive offerings given the broad shelf registration.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001437749-26-019194 |
| Document: 0001437749-26-019194-index-headers.html | 0001437749-26-019194 |
| Document: 0001437749-26-019194-index.html | 0001437749-26-019194 |
| Document: 0001437749-26-019194.txt | 0001437749-26-019194 |
Track record
4 reports on NRXPW
The track record builds as more bullish or bearish reports settle.
Filters
- Jun 4, 202623w ago 8-K Bearish 6/10 No price data
- Jun 3, 202623w ago 424B5 Bearish 6/10 No price data
- Jun 2, 202623w ago 424B5 Bearish 6/10 Viewing No price data
- May 22, 202625w ago 25-NSE Bearish 8/10 Entry $0.0142 to $0.0142 · 0.00% +1.21% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers